Friday, March 06, 2015 4:08:42 PM
i spoke with the VP of Bus Dev yesterday...
Douglas Hicks
Vice-President, Business Development
302-355-2313
Here is the jest///
[me] - I'm an investor... invested based on Ebola/Zmapp possible connection, could you comment on the connection iBio has to Zmapp, or other ebola targeting vaccines, either directly or as licensed technologies being used to develop by 3rd parties
[doug] - Who are you ?
[me] - ... my name, i'm an investor... repeated question.
[doug] - I will have someone call you..
[me] - Thanks Doug, but can you answer this... do you not have the answers, or can you not comment on my questions?
[doug] - I'll have someone call you..
[me] - thanks again, could you possibly comment if ANY company/party is using iBio licenses or patents (either with or without ibio's permission) to develop any products related to the treatment or trial of potential treatments of ebola.
[doug] - I've taken notes and will have someone call you.
......
Douglas Hicks
Vice-President, Business Development
302-355-2313
Here is the jest///
[me] - I'm an investor... invested based on Ebola/Zmapp possible connection, could you comment on the connection iBio has to Zmapp, or other ebola targeting vaccines, either directly or as licensed technologies being used to develop by 3rd parties
[doug] - Who are you ?
[me] - ... my name, i'm an investor... repeated question.
[doug] - I will have someone call you..
[me] - Thanks Doug, but can you answer this... do you not have the answers, or can you not comment on my questions?
[doug] - I'll have someone call you..
[me] - thanks again, could you possibly comment if ANY company/party is using iBio licenses or patents (either with or without ibio's permission) to develop any products related to the treatment or trial of potential treatments of ebola.
[doug] - I've taken notes and will have someone call you.
......
Recent IBIO News
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 10:42:16 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:19:08 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 06:26:31 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 12:16:02 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/12/2026 08:31:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 08:18:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 08:15:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 08:16:28 PM
- iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors • GlobeNewswire Inc. • 05/08/2026 11:15:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/29/2026 01:11:36 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 04/17/2026 09:13:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2026 01:00:47 PM
- iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia • GlobeNewswire Inc. • 04/08/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 08:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 11:31:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 11:30:09 AM
- iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) • GlobeNewswire Inc. • 03/16/2026 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 11:04:38 AM
- iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss • GlobeNewswire Inc. • 03/09/2026 11:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/06/2026 10:25:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2026 09:49:58 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/27/2026 09:23:59 PM
